Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

Latest Prostate Cancer News and Research

Addition of hormone therapy to radiotherapy treatments improves survival in prostate cancer patients

Prostate cancer is the leading cause of cancer in men worldwide, and radiotherapy is one of the common forms of treatment.

18 Jan 2022

New genomic signature can spot aggressive tumor cells from primary, untreated prostate cancers

Many cases of early prostate cancer are dominated by cells that are slow-growing, often leading to a clinical decision to monitor for progression before initiating treatments that can have adverse side effects.

18 Jan 2022

Researchers implement and evaluate an educational intervention for prostate cancer

Prostate cancer is the second deadliest cancer in men in the United States. The incidence of prostate cancer in Black men is nearly 60% greater than the incidence in white men.

13 Jan 2022

Study shows AI systems can accurately identify and grade prostate cancer

Researchers at Karolinska Institutet in Sweden have together with international collaborators completed a comprehensive international validation of artificial intelligence (AI) for diagnosing and grading prostate cancer.

13 Jan 2022

New trial could transform the way of caring for people with neuroendocrine tumors

A revolutionary new way of caring for people with neuroendocrine tumors (NETs) will be trialed in the coming months, with the Flinders University-led project aiming to improve patient quality of life and develop a cost-effective system that can be implemented across other rare cancers in the future.

13 Jan 2022

Long-excluded uterine cancer patients are step closer to 9/11 benefits

Tammy Kaminski can still recall the taste of benzene, a carcinogenic byproduct of burning jet fuel. For nine months after the 9/11 attacks, she volunteered for eight hours every Saturday at St. Paul's Chapel, just around the corner from ground zero in New York City.

13 Jan 2022

MAPK4 may play a key role in triple-negative breast cancer

Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly.

12 Jan 2022

New appropriate use criteria for prostate-specific membrane antigen PET imaging published

The Society of Nuclear Medicine and Molecular Imaging and peer medical groups have issued appropriate use criteria (AUC) for prostate-specific membrane antigen (PSMA) PET imaging.

7 Jan 2022

The war on cancer at 50: The origin story begins with a socialite citizen-lobbyist

The roots of the National Cancer Act can be traced to a small home in Watertown, Wisconsin. In the early 1900s, a girl named Mary tagged along when her mother went to visit their laundress, Mrs. Belter, who had breast cancer.

6 Jan 2022

Black men with prostate cancer may have improved response to radiation therapy than white men

UCLA Jonsson Comprehensive Cancer Center researchers leading a meta-analysis of seven randomized trials found an "unexpected result": Although Black men appeared to have more aggressive disease when they enrolled in clinical trials of radiation therapy for prostate cancer, their treatment outcomes and disease-specific outcomes were better than those of their white counterparts.

30 Dec 2021

Researchers identify novel cancer markers in patients with aggressive prostate cancer

Prostate cancer is the most commonly diagnosed cancer in men and is among the top five causes of cancer-related death. In most cases, prostate cancer can be successfully treated but there is a group of patients who suffer an aggressive course and often fatal outcome.

22 Dec 2021

A Day in the Life of A Clinical Geneticist

In this interview, we spoke to Dr. Julian Barwell, a clinical geneticist, about his day-to-day roles and responsibilities as well as his career highlights.

17 Dec 2021

The Ronald Weiser Center for Prostate Cancer to be established with $30 million gift

University of Michigan Regent Ron Weiser has committed $30 million to Michigan Medicine to establish an innovative, patient-focused program in prostate cancer.

16 Dec 2021

Novel technique developed to observe cancer cells’ metastatic potential

When cancer cells metastasize, they morph, becoming missile-shaped in order to penetrate into other tissues throughout the body.

16 Dec 2021

Study provides new insights into molecular drivers of treatment resistance in prostate cancer

An international research team co-led by scientists at Roswell Park Comprehensive Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified an important accelerator of treatment-resistant prostate cancer.

14 Dec 2021

Henry Ford surgeons use unique approach to perform first precision prostatectomy

Surgeons at Henry Ford Health System's Vattikuti Urology Institute performed what is believed to be the first precision prostatectomy through the bladder using a single port robotic surgical system.

13 Dec 2021

Impact of tumor environments on susceptibility and course of disease in those infected with SARS-CoV-2

A review assessed the impact of "hot" vs. "cold" immune/tumor environments (and associated therapies) on susceptibility and disease course in subjects with these two types of tumors and infected with SARS-CoV-2 to decipher the mechanisms that drive these adverse outcomes in COVID-19 infected cancer patients.

13 Dec 2021